转移性结直肠癌治疗的新进展_Mar_2014.ppt

下载文档

10
0
约3.22万字
约 72页
2018-01-04 发布于江苏
举报
版权申诉
保障服务

转移性结直肠癌治疗的新进展_Mar_2014.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

转移性结直肠癌治疗的新进展_Mar_2014

New Developments in the Treatment of Colorectal Cancer * * FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; mFOLFOX, modified 5-fluorouracil, leucovorin, and oxaliplatin; sLV5FU2, simplified leucovorin plus bolus and infusional fluorouracil. OS, overall survival; PFS, progression-free survival. * * * ECOG, Eastern Cooperative Oncology Group; mCRC, metastatic colorectal cancer; PS, performance score; q3w, every 3 weeks. * * Bev, bevacizumab; ITT, intention to treat; XELOX, capecitabine, oxaliplatin. CR, complete response; FOLFIRI, leucovorin/fluorouracil/irinotecan; mCRC, metastatic colorectal cancer; PR, partial response; SD, stable disease. * OS, overall survival; PFS, progression-free survival. * 5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; IV, intravenously; LV, leucovorin; mCRC, metastatic colorectal cancer; q2w, every 2 weeks; XRT, external-beam radiotherapy. * Bev, bevacizumab; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; mCRC, metastatic colorectal cancer; OS, overall survival. VELOUR 研究 : 按贝伐单抗分层OS Tabernero J, et al. Eur J Cancer. 2013;[Epub ahead of print]. OS (%) 100 80 60 40 20 0 Mos 0 3 6 9 12 15 18 21 24 27 30 33 36 39 HR: 0.862 (95.34% CI: 0.673-1.104) Placebo/FOLFIRIMedian: 11.7 mos Aflibercept/FOLFIRIMedian: 12.5 mos Pts at Risk, n PlaceboAFL 187186 170178 138150 115121 8189 5459 3736 2222 1313 Previous Bevacizumab OS (%) 100 80 60 40 20 0 Mos 0 3 6 9 12 15 18 21 24 27 30 33 36 39 HR: 0.788 (95.34% CI: 0.699-0.927) Placebo/FOLFIRIMedian: 12.4 mos Aflibercept/FOLFIRIMedian: 13.9 mos Pts at Risk, n PlaceboAFL 427426 403388 347348 286295 205222 139157 94112 6582 3862 No Previous Bevacizumab (阿帕西普) (阿帕西普) ziv-Aflibercept (阿帕西普): 毒性 Increased Grade 3/4 AEs in Aflibercept Arm, % FOLFIRI + Aflibercept (n = 611) FOLFIRI + Placebo (n = 605)